Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2007-12, Vol.133 (12), p.1025-1025
Main Authors: Fedders, M., Hartmann, M., Schneider, A., Kath, R., Camara, O., Oelschläger, H.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c245t-55adf874404ac2c7a085c50408020b8018a38801233fdc4e4e542636fc688fd93
cites
container_end_page 1025
container_issue 12
container_start_page 1025
container_title Journal of cancer research and clinical oncology
container_volume 133
creator Fedders, M.
Hartmann, M.
Schneider, A.
Kath, R.
Camara, O.
Oelschläger, H.
description
doi_str_mv 10.1007/s00432-007-0313-y
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_220541043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1363521171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-55adf874404ac2c7a085c50408020b8018a38801233fdc4e4e542636fc688fd93</originalsourceid><addsrcrecordid>eNptkctOHDEQRa2ISBlIPiA7K3sTP6c7ywjlJYHYwLpVuG3GxN3VsT3AfGd-KNVMlmxct-xbR1Zdxj4qea6k7D5XKa3RgqSQRhlxeMM2ar1RxrgTtpGqU8JptX3HTmt9kNS7Tm_Y3ysov_FRTDiGnOZ7HrHwtgscxinNqbYCLeHMMfIlk5z3E4cZMt7vQyU18gV8Tg2eQ-ZQeUylNkGkwP0uTEioAsthfXoK-cXScMEWPMwv4zktWHGCzEd8xrK_Sz7Nq60Gj_P4CuoptR0PC530Y5rDRyiJaB4KjRLqPXsbIdfw4X89Y7ffv91c_BSX1z9-XXy9FF5b14RzMMa-s1Za8Np3IHvnnbSyl1re9VL1YHoq2pg4ehtscFZvzTb6bd_H8Ys5Y5-O3KXgH1pHGx5wX2g5ddBaOqsoEjKpo8kXrLWEOCwlTVAOg5LDGt1wjG5Y5RrdcDD_AK-kkm0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220541043</pqid></control><display><type>article</type><title>Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma</title><source>Springer Nature</source><creator>Fedders, M. ; Hartmann, M. ; Schneider, A. ; Kath, R. ; Camara, O. ; Oelschläger, H.</creator><creatorcontrib>Fedders, M. ; Hartmann, M. ; Schneider, A. ; Kath, R. ; Camara, O. ; Oelschläger, H.</creatorcontrib><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-007-0313-y</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><ispartof>Journal of cancer research and clinical oncology, 2007-12, Vol.133 (12), p.1025-1025</ispartof><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c245t-55adf874404ac2c7a085c50408020b8018a38801233fdc4e4e542636fc688fd93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Fedders, M.</creatorcontrib><creatorcontrib>Hartmann, M.</creatorcontrib><creatorcontrib>Schneider, A.</creatorcontrib><creatorcontrib>Kath, R.</creatorcontrib><creatorcontrib>Camara, O.</creatorcontrib><creatorcontrib>Oelschläger, H.</creatorcontrib><title>Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma</title><title>Journal of cancer research and clinical oncology</title><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNptkctOHDEQRa2ISBlIPiA7K3sTP6c7ywjlJYHYwLpVuG3GxN3VsT3AfGd-KNVMlmxct-xbR1Zdxj4qea6k7D5XKa3RgqSQRhlxeMM2ar1RxrgTtpGqU8JptX3HTmt9kNS7Tm_Y3ysov_FRTDiGnOZ7HrHwtgscxinNqbYCLeHMMfIlk5z3E4cZMt7vQyU18gV8Tg2eQ-ZQeUylNkGkwP0uTEioAsthfXoK-cXScMEWPMwv4zktWHGCzEd8xrK_Sz7Nq60Gj_P4CuoptR0PC530Y5rDRyiJaB4KjRLqPXsbIdfw4X89Y7ffv91c_BSX1z9-XXy9FF5b14RzMMa-s1Za8Np3IHvnnbSyl1re9VL1YHoq2pg4ehtscFZvzTb6bd_H8Ys5Y5-O3KXgH1pHGx5wX2g5ddBaOqsoEjKpo8kXrLWEOCwlTVAOg5LDGt1wjG5Y5RrdcDD_AK-kkm0</recordid><startdate>20071201</startdate><enddate>20071201</enddate><creator>Fedders, M.</creator><creator>Hartmann, M.</creator><creator>Schneider, A.</creator><creator>Kath, R.</creator><creator>Camara, O.</creator><creator>Oelschläger, H.</creator><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20071201</creationdate><title>Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma</title><author>Fedders, M. ; Hartmann, M. ; Schneider, A. ; Kath, R. ; Camara, O. ; Oelschläger, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-55adf874404ac2c7a085c50408020b8018a38801233fdc4e4e542636fc688fd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fedders, M.</creatorcontrib><creatorcontrib>Hartmann, M.</creatorcontrib><creatorcontrib>Schneider, A.</creatorcontrib><creatorcontrib>Kath, R.</creatorcontrib><creatorcontrib>Camara, O.</creatorcontrib><creatorcontrib>Oelschläger, H.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fedders, M.</au><au>Hartmann, M.</au><au>Schneider, A.</au><au>Kath, R.</au><au>Camara, O.</au><au>Oelschläger, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><date>2007-12-01</date><risdate>2007</risdate><volume>133</volume><issue>12</issue><spage>1025</spage><epage>1025</epage><pages>1025-1025</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00432-007-0313-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0171-5216
ispartof Journal of cancer research and clinical oncology, 2007-12, Vol.133 (12), p.1025-1025
issn 0171-5216
1432-1335
language eng
recordid cdi_proquest_journals_220541043
source Springer Nature
title Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Markov-modeling%20for%20the%20administration%20of%20platinum%20analogues%20and%20paclitaxel%20as%20first-line%20chemotherapy%20as%20well%20as%20topotecan%20and%20liposomal%20doxorubicin%20as%20second-line%20chemotherapy%20with%20epithelial%20ovarian%20carcinoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Fedders,%20M.&rft.date=2007-12-01&rft.volume=133&rft.issue=12&rft.spage=1025&rft.epage=1025&rft.pages=1025-1025&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-007-0313-y&rft_dat=%3Cproquest_cross%3E1363521171%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c245t-55adf874404ac2c7a085c50408020b8018a38801233fdc4e4e542636fc688fd93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220541043&rft_id=info:pmid/&rfr_iscdi=true